Research
Cracking cancer’s code: New research identifies novel drug target for acute myeloid leukemia treatment
June 23, 2026
By Claire Kowalick Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse and have many different drivers. A longtime goal for scientists in this field is to […]
Drug-discovery breakthrough for large and polar drugs: Discovery of chemical endocytosis could redefine precision medicine
June 23, 2026
By Claire Kowalick A team of scientists, notably Zhengyu Wang, PhD, assistant professor in the department of pharmacology at The University of Texas at San Antonio and the Barshop Institute, led by Hong-yu Li, PhD, professor of medicinal chemistry and chemical biology with the department of pharmacology and the Barshop Institute, together with two other […]
Targeted drug offers hope for safe, effective senolytic treatment for liver disease, cancer
June 23, 2026
By Claire Kowalick San Antonio has one of the highest rates of metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States, largely driven by high rates of obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or cirrhosis and liver cancer, posing a […]
Drug found to double survival time for glioblastoma patients
June 23, 2026
By Steven Lee A drug developed at The University of Texas at San Antonio has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that a unique investigational drug formulation called Rhenium Obisbemeda (186RNL) more than doubled median […]
Uncovering how some cancers outsmart the immune system
June 23, 2026
By Claire Kowalick For years, scientists have found the overexpression of a specific protein called FOXM1 in a wide range of cancers, including ovarian, breast and pediatric cancers. A recent study by scientists at The University of Texas at San Antonio has now led to understanding its exact role in cancer development and is the […]
Key DNA complex connected to PARP inhibitor cancer-drug resistance discovered
June 23, 2026
By Claire Kowalick Scientists have made one of the most important discoveries to date in the study and treatment of BRCA1-deficient cancers and drug resistance. Approximately one in 300 Americans have a pathogenic mutation in the BRCA1 or BRCA2 gene, placing them at an elevated risk of developing certain cancers, especially breast and ovarian cancer. […]
Promising drug for treating brain tumors stemming from breast cancer
July 30, 2025
“We knew that the drug has been effective in the treatment of breast cancer, but its usefulness in the treatment of resulting brain tumors has been unclear. Our trial, however, revealed that it could achieve concentrations of inhibitors inside the tumors sufficient to benefit patients, and with minimal side effects, which is very promising for […]
Breaking new ground with BRCA1 research at UT Health San Antonio
July 30, 2025
A study led by the UT Health San Antonio sheds light on a novel role of breast cancer gene 1 (BRCA1) in tumor suppression for breast and ovarian cancers. Individuals with inherited mutations in BRCA1 are predisposed to breast, ovarian and other cancers. BRCA1 helps prevent cancer by repairing damaged DNA, but how it does […]
UT Health San Antonio awarded $12.6 million grant for cancer research, understanding drug resistance
July 30, 2025
“This investment in research is a commitment to pioneering treatments in cancer care. The funding supports our mission to make significant strides in bringing hope and fighting cancer.” – Lei Zheng, MD, PhD, executive director of Mays Cancer Center. The University of Texas Health Science Center at San Antonio received a collaborative $12.6 million […]
UT Health San Antonio’s world-renowned expert in BRCA research honored for global contributions
July 30, 2025
Patrick Sung, DPhil, director of The University of Texas Health Science Center at San Antonio’s Greehey Children’s Cancer Research Institute and associate dean for research at UT Health San Antonio, is the latest recipient of the 2024 Basser Global Prize. A leading researcher in DNA damage repair and cancer biology, Sung has been awarded the […]
Mays Cancer Center identifies possible markers to detect metastatic lung cancer sooner
July 30, 2025
Researchers at Mays Cancer Center at The University of Texas Health Science Center at San Antonio have identified protein markers that could signal the development of metastatic lung cancer sooner – making it possible for new treatment. The findings led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes […]
Mays Cancer Center partners with American Cancer Society to diagnose lung cancer sooner in South Texans
July 30, 2025
“This support is invaluable in helping our multidisciplinary team provide early detection and life-saving care to those at risk. We are improving outcomes and saving lives in the fight against lung cancer in a way that no other integrated academic health system in our region can do.” – Ramon Cancino, MD, MBA, MS, FAACP, executive […]